Skip to main content

Table 2 Results from the multivariate generalized linear mixed modeling under the Bayesian framework. The data represent the median and 95% credible intervals for the outcome measures MDS-UPDRS-II, MDS-UPDRS-I, and Imbalance

From: Predicting the multi-domain progression of Parkinson’s disease: a Bayesian multivariate generalized linear mixed-effect model

 

Median

2.50%

97.50%

MDS-UPDRS-II (motor)

 Intercept

13.522

0.076

25.197

 Time

−0.042

−0.095

0.011

 Age at Baseline

0.035

−0.147

0.211

 Education

−0.108

−0.604

0.419

 Gender (=Male)

0.805

−2.381

3.904

 DOI*

0.549

0.169

0.919

 HAMD*

0.283

0.087

0.492

 MoCA*

−0.320

−0.584

−0.052

 LEDD

1.066

−0.570

2.612

MDS-UPDRS-I (non-motor)

 Intercept

26.351

10.126

38.947

 Time

−0.016

−0.075

0.046

 Age at Baseline

0.075

−0.098

0.250

 Education*

−0.575

−1.075

−0.107

 Gender (=Male)

−1.925

−5.203

1.036

 DOI

0.037

−0.306

0.397

 HAMD*

0.439

0.217

0.693

 MoCA

−0.311

−0.609

0.008

 LEDD

0.360

−1.250

1.993

Imbalance

 Intercept

6.096

−6.903

23.289

 Time*

−0.109

−0.579

−0.001

 Age at Baseline

0.181

−0.021

0.853

 Education

−0.148

−1.184

0.823

 Gender (=Male)*

−4.657

−21.182

−0.790

 DOI

0.312

−0.027

2.233

 HAMD

0.023

−0.302

0.541

 MoCA*

−0.589

−2.336

−0.164

 LEDD*

2.827

0.675

11.893

  1. Abbreviations: MDS-UPDRS the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale, DOI duration of illness, HAMD Hamilton Depression Rating Scale, MoCA the Montreal Cognitive Assessment, LEDD Levodopa equivalent daily dose
  2. *95% credible interval does not include 0, indicating the signifiance 
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us